MT Newswires
Evommune Says its Atopic Dermatitis Treatment Achieved 'Statistically Significant' Outcomes in Proof-of-Concept Trial
➖
AI Sentiment
Neutral
5/10
Evommune Inc. News
Latest updates and market news for EVMN
3 news
Feb 5 - Feb 11, 2026
Page 1
Investor's Business Daily
Evommune Nearly Doubles — Has Dupixent Met Its Match In Eczema?
📈
AI Sentiment
Highly Positive
9/10
Business Wire
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis
📈
AI Sentiment
Highly Positive
9/10
Share this news page